Michael D. Hogarty

Also affiliated with Pennsylvania Hospital, University of Pennsylvania

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 22 papers. Top paper: “Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations”.

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

Nature Communications(2020)10.1038/s41467-020-18987-4

N/A

0DataRank · unranked

174 citations

Yanling Liu, Xiaotu Ma, Alexander M. Gout, Kohei Hagiwara, Xin Zhou +19 more

MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Nature Communications(2020)10.1038/s41467-020-14682-6

N/A

0DataRank · unranked

129 citations

Sara M. Federico, Xiang Chen, Yiping Fan, Beisi Xu, Elizabeth Stewart +32 more

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells

Frontiers in Immunology(2020)10.3389/fimmu.2020.00873

N/A

0DataRank · unranked

34 citations

Spyridon Karageorgos, Michael D. Hogarty, Hamid Bassiri, Kevin O. McNerney

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.007

N/A

0DataRank · unranked

31 citations

Arlene Naranjo, Emily Hibbitts, Julie M. Gastier‐Foster, Rochelle Bagatell, Meredith S. Irwin +5 more

Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥18 months with unfavorable histology and without MYCN amplification: A Children’s Oncology Group (COG) report.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10502

N/A

0DataRank · unranked

0 citations

Arlene Naranjo, Emily Hibbitts, Xiangming Ding, Rachelle Tibbetts, Rebekah Kennedy +7 more

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Nature Communications(2021)10.1038/s41467-020-20785-x

N/A

0DataRank · unranked

157 citations

Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri +5 more

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.006

N/A

0DataRank · unranked

33 citations

Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney +17 more

A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma

Cancers(2021)10.3390/cancers13081807

N/A

0DataRank · unranked

6 citations

Stefania Purgato, Michelle J. Henderson, Simone Di Giacomo, Amanda J. Russell, Paolo Pigini +30 more

Epigenetic state determines inflammatory sensing in neuroblastoma

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.01.27.428523

N/A

0DataRank · unranked

6 citations

Liron D. Grossmann, May M. Dong, Jessica L. Dessau, Patricia Brafford, Darya Volgina +8 more

Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance

The Medicine Forum(2021)10.1101/2021.03.01.433120

N/A

0DataRank · unranked

2 citations

David M. Booth, J. Škoda, Madison C. Pedrotty, Jennifer Vogel, Kangning Liu +13 more

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in TH-MYCN mice

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.06.09.447746

N/A

0DataRank · unranked

1 citations

Spyridon Karageorgos, George D. Ferry, Adam J. Wolpaw, Chakkapong Burudpakdee, Priya Khurana +5 more

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy

OncoImmunology(2022)10.1080/2162402x.2022.2075204

N/A

0DataRank · unranked

22 citations

Spyridon Karageorgos, GM Ferry, AJ Wolpaw, Chakkapong Burudpakdee, Priya Khurana +6 more

Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10013

N/A

0DataRank · unranked

1 citations

Hannah Bender, Meredith S. Irwin, Michael D. Hogarty, Robert P. Castleberry, John M. Maris +4 more

Data from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

(2023)10.1158/0008-5472.c.6497243

N/A

0DataRank · unranked

0 citations

Murray D. Norris, Kimberly A. Davis, Xueyuan Liu, Nicholas F. Evageliou, Candace S. Hayes +17 more

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures

Cancer(2024)10.1002/cncr.35301

N/A

0DataRank · unranked

28 citations

Peter Dimitrion, Oussama Abla, Simon Bomken, Patrick Campbell, Matthew Collin +27 more

Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

Journal of Pediatric Surgery(2024)10.1016/j.jpedsurg.2024.161896

N/A

0DataRank · unranked

6 citations

E. Stanton Adkins, Peter Mattei, Fredric A. Hoffer, Sandra L. Wootton‐Gorges, Wendy B. London +14 more

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis

British Journal of Haematology(2024)10.1111/bjh.19376

N/A

0DataRank · unranked

16 citations

Howard Lin, Akanksha Batajoo, Erin C. Peckham‐Gregory, Vivekanudeep Karri, Whitney Stanton +26 more

Improvements in Children’s Oncology Group neuroblastoma risk stratification through a change in age cut-off and use of INRGSS

Translational Pediatrics(2024)10.21037/tp-24-319

N/A

0DataRank · unranked

2 citations

Hannah Bousquet, Meredith S. Irwin, Michael D. Hogarty, Susan L. Cohn, Wendy B. London

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Pediatric Blood & Cancer(2024)10.1002/pbc.31407

N/A

0DataRank · unranked

1 citations

Howard M. Katzenstein, Arlene Naranjo, Sheena C. Tenney, Lulu Chen, Wendy B. London +11 more

Reprogramming neuroblastoma by diet-enhanced polyamine depletion

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.01.07.573662

N/A

0DataRank · unranked

5 citations

Lifeng Yang, Matthew J. McBride, Christina S. Turn, Wenyun Lu, Caroline Eigenmann +14 more

Reprogramming neuroblastoma by diet-enhanced polyamine depletion

Nature(2025)10.1038/s41586-025-09564-0

N/A

0DataRank · unranked

20 citations

Christina S. Turn, Yuan Yuan, Wenyun Lu, Lifeng Yang, Matthew J. McBride +17 more

High-dose DFMO alters protein translation in neuroblastoma

Neoplasia(2025)10.1016/j.neo.2025.101215

N/A

0DataRank · unranked

3 citations

Kangning Liu, Rohan Vemu, Elizabeth W. Scadden, Yimei Li, Annette Vu +2 more